Aethlon Medical, Inc. (AEMD)

Over the past six months, Aethlon Medical, Inc.'s stock price has declined significantly. In February 2026, the company reported its Q3 2026 earnings, missing analysts' expectations. Other events include advancing to the final cohort in an oncology clinical trial, completing pre-funded warrant exercises, and engaging Maxim Group LLC to evaluate strategic opportunities in March 2026. A reverse stock split was announced in October 2023.

Seasonality analysis for Aethlon Medical, Inc. primarily refers to its stock performance rather than the demand for its products and services. Historically, January has been the strongest month for AEMD stock, while April tends to be the weakest. The observed seasonality is related to stock trading patterns over 27 years of historical data.

Aethlon Medical, Inc. is a medical therapeutic company focused on developing novel immunotherapeutic devices to treat cancer and viral infections. The company's primary product is the Hemopurifier, a clinical-stage immunotherapeutic device designed for applications in cancer, life-threatening viral infections, and organ transplantation. The Hemopurifier has received FDA Breakthrough Device designation for treating individuals with advanced cancer unresponsive to standard therapy and for life-threatening viruses not addressed by approved treatments.

Aethlon Medical, Inc. is headquartered in San Diego, California, United States. The company is conducting a clinical trial of the Hemopurifier in cancer patients with solid tumors in Australia. AEMD stock is listed on the NASDAQ and also trades on the Munich Stock Exchange, Frankfurt Stock Exchange, and London Stock Exchange.

Aethlon Medical has a news sentiment score of 1.14. Analyst coverage indicates a consensus rating of "Reduce," based on one hold rating and one sell rating. The company has been the subject of a limited number of research reports in the past 90 days. The negative analyst outlook and missed earnings could contribute to a challenging perception.

The ownership structure of Aethlon Medical, Inc. is a mix of institutional, insider, and public/individual investors. Institutional investors own approximately 1.09% to 1.99% of the company's stock, insiders hold about 26.68%, and public companies and individual investors own approximately 72.13%. Major institutional shareholders include Ikarian Capital, LLC, Morgan Stanley, Citigroup Inc, Group One Trading, L.p., BlackRock, Inc., Bank Of America Corp /de/, Wells Fargo & Company/mn, and Danske Bank A/s. Angela Rossetti is noted as owning the most shares of Aethlon Medical Inc.